Does the media refer more to RNAC or JANX?

In the previous week, Janux Therapeutics had 2 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 4 mentions for Janux Therapeutics and 2 mentions for Cartesian Therapeutics. Janux Therapeutics' average media sentiment score of 1.34 beat Cartesian Therapeutics' score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Janux Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RNAC or SVRA?

In the previous week, Savara had 1 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for Savara and 2 mentions for Cartesian Therapeutics. Savara's average media sentiment score of 1.43 beat Cartesian Therapeutics' score of 0.00 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CVAC or RNAC?

Cartesian Therapeutics has a consensus target price of $32.60, indicating a potential upside of 257.46%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cartesian Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Does the media refer more to RNAC or AVTX?

In the previous week, Avalo Therapeutics had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 6 mentions for Avalo Therapeutics and 2 mentions for Cartesian Therapeutics. Avalo Therapeutics' average media sentiment score of 0.92 beat Cartesian Therapeutics' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalo Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLDB or RNAC?

In the previous week, Solid Biosciences and Solid Biosciences both had 2 articles in the media. Solid Biosciences' average media sentiment score of 0.56 beat Cartesian Therapeutics' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cartesian Therapeutics (RNAC) Competitors

$9.12 +0.04 (+0.44%)

As of 04:00 PM Eastern

Compare

RNAC vs. JANX, SVRA, CVAC, AVTX, and SLDB

Should you buy Cartesian Therapeutics stock or one of its competitors? Cartesian Therapeutics's main competitors and comparable companies include Janux Therapeutics (JANX), Savara (SVRA), CureVac (CVAC), Avalo Therapeutics (AVTX), and Solid Biosciences (SLDB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cartesian Therapeutics compare to Janux Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Janux Therapeutics has higher revenue and earnings than Cartesian Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	98.53	-$130.30M	-$5.94	N/A
Janux Therapeutics	$10M	121.06	-$113.62M	-$1.64	N/A

Cartesian Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, suggesting that its share price is 153% more volatile than the broader market.

Cartesian Therapeutics presently has a consensus target price of $32.60, suggesting a potential upside of 257.46%. Janux Therapeutics has a consensus target price of $36.46, suggesting a potential upside of 84.15%. Given Cartesian Therapeutics' higher possible upside, equities analysts plainly believe Cartesian Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Janux Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%
Janux Therapeutics	N/A	-11.89%	-11.13%

In the previous week, Janux Therapeutics had 2 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 4 mentions for Janux Therapeutics and 2 mentions for Cartesian Therapeutics. Janux Therapeutics' average media sentiment score of 1.34 beat Cartesian Therapeutics' score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Janux Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Janux Therapeutics beats Cartesian Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Savara?

Cartesian Therapeutics (NASDAQ:RNAC) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Cartesian Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Savara has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

Savara has lower revenue, but higher earnings than Cartesian Therapeutics. Savara is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	98.53	-$130.30M	-$5.94	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Savara has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%
Savara	N/A	-90.28%	-68.95%

In the previous week, Savara had 1 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for Savara and 2 mentions for Cartesian Therapeutics. Savara's average media sentiment score of 1.43 beat Cartesian Therapeutics' score of 0.00 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cartesian Therapeutics presently has a consensus target price of $32.60, suggesting a potential upside of 257.46%. Savara has a consensus target price of $10.14, suggesting a potential upside of 88.88%. Given Cartesian Therapeutics' higher probable upside, equities research analysts clearly believe Cartesian Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Savara beats Cartesian Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to CureVac?

CureVac (NASDAQ:CVAC) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

In the previous week, Cartesian Therapeutics had 2 more articles in the media than CureVac. MarketBeat recorded 2 mentions for Cartesian Therapeutics and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 equaled Cartesian Therapeutics'average media sentiment score.

Company	Overall Sentiment
CureVac	Neutral
Cartesian Therapeutics	Neutral

CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Cartesian Therapeutics has a consensus target price of $32.60, indicating a potential upside of 257.46%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

CureVac has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Cartesian Therapeutics	$2.80M	98.53	-$130.30M	-$5.94	N/A

17.3% of CureVac shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CureVac has a net margin of 199.92% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

Summary

Cartesian Therapeutics beats CureVac on 8 of the 15 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Avalo Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Avalo Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%
Avalo Therapeutics	N/A	-58.03%	-48.22%

In the previous week, Avalo Therapeutics had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 6 mentions for Avalo Therapeutics and 2 mentions for Cartesian Therapeutics. Avalo Therapeutics' average media sentiment score of 0.92 beat Cartesian Therapeutics' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalo Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cartesian Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Avalo Therapeutics has lower revenue, but higher earnings than Cartesian Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	98.53	-$130.30M	-$5.94	N/A
Avalo Therapeutics	$60K	16,982.83	-$78.26M	-$4.37	N/A

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cartesian Therapeutics currently has a consensus target price of $32.60, suggesting a potential upside of 257.46%. Avalo Therapeutics has a consensus target price of $45.10, suggesting a potential upside of 137.37%. Given Cartesian Therapeutics' higher probable upside, research analysts clearly believe Cartesian Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Avalo Therapeutics beats Cartesian Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Solid Biosciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

In the previous week, Solid Biosciences and Solid Biosciences both had 2 articles in the media. Solid Biosciences' average media sentiment score of 0.56 beat Cartesian Therapeutics' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solid Biosciences currently has a consensus price target of $18.18, indicating a potential upside of 74.49%. Cartesian Therapeutics has a consensus price target of $32.60, indicating a potential upside of 257.46%. Given Cartesian Therapeutics' higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Cartesian Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Cartesian Therapeutics	$2.80M	98.53	-$130.30M	-$5.94	N/A

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cartesian Therapeutics beats Solid Biosciences on 8 of the 14 factors compared between the two stocks.

Get Cartesian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNAC vs. The Competition

Export

Metric	Cartesian Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$274.72M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-1.54	12.66	273.28	25.38
Price / Sales	98.53	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	-2.20	16.29	12.89	6.14
Net Income	-$130.30M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-8.53%	-1.37%	-0.33%	-1.47%
1 Month Performance	15.88%	11.07%	6.51%	2.47%
1 Year Performance	-11.02%	53.71%	25.19%	15.84%

Cartesian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNAC Cartesian Therapeutics	1.6931 of 5 stars	$9.12 +0.4%	$32.60 +257.5%	-7.7%	$274.72M	$2.80M	N/A	64
JANX Janux Therapeutics	2.4997 of 5 stars	$18.89 +3.7%	$36.46 +93.0%	-13.8%	$1.11B	$10M	N/A	30
SVRA Savara	2.2297 of 5 stars	$5.35 -0.7%	$10.14 +89.6%	+65.0%	$1.11B	N/A	N/A	20	Positive News
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
AVTX Avalo Therapeutics	3.2097 of 5 stars	$18.95 -2.0%	$45.10 +138.0%	+114.4%	$1.04B	$60K	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNAC) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. JANX, SVRA, CVAC, AVTX, and SLDB

How does Cartesian Therapeutics compare to Janux Therapeutics?

Summary

How does Cartesian Therapeutics compare to Savara?

Summary

How does Cartesian Therapeutics compare to CureVac?

Summary

How does Cartesian Therapeutics compare to Avalo Therapeutics?

Summary

How does Cartesian Therapeutics compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. JANX, SVRA, CVAC, AVTX, and SLDB

How does Cartesian Therapeutics compare to Janux Therapeutics?

Which has preferable valuation and earnings, RNAC or JANX?

Which has more volatility and risk, RNAC or JANX?

Do analysts recommend RNAC or JANX?

Do institutionals and insiders hold more shares of RNAC or JANX?

Is RNAC or JANX more profitable?

Does the media refer more to RNAC or JANX?

Summary

How does Cartesian Therapeutics compare to Savara?

Which has more risk & volatility, RNAC or SVRA?

Which has better valuation and earnings, RNAC or SVRA?

Is RNAC or SVRA more profitable?

Does the media refer more to RNAC or SVRA?

Do institutionals and insiders hold more shares of RNAC or SVRA?

Do analysts rate RNAC or SVRA?

Summary

How does Cartesian Therapeutics compare to CureVac?

Does the media favor CVAC or RNAC?

Which has more volatility & risk, CVAC or RNAC?

Do analysts rate CVAC or RNAC?

Which has stronger valuation and earnings, CVAC or RNAC?

Do institutionals & insiders have more ownership in CVAC or RNAC?

Is CVAC or RNAC more profitable?

Summary

How does Cartesian Therapeutics compare to Avalo Therapeutics?

Is RNAC or AVTX more profitable?

Does the media refer more to RNAC or AVTX?

Which has more risk and volatility, RNAC or AVTX?

Which has preferable earnings & valuation, RNAC or AVTX?

Do institutionals and insiders hold more shares of RNAC or AVTX?

Do analysts prefer RNAC or AVTX?

Summary

How does Cartesian Therapeutics compare to Solid Biosciences?

Which has more risk and volatility, SLDB or RNAC?

Is SLDB or RNAC more profitable?

Does the media favor SLDB or RNAC?

Do analysts recommend SLDB or RNAC?

Which has stronger valuation & earnings, SLDB or RNAC?

Do insiders & institutionals believe in SLDB or RNAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools